Despite the existence of numerous antibiotics, recurrence of certain infections, such as those caused by Clostridium difficile, remains a clinical challenge. The root of the problem is the detrimental effect of antibiotics on the function and composition of intestinal commensals. To tackle C. difficile refractoriness to treatment and infection recurrence, scientists are trying to understand how a healthy microbiota may keep this pathogen at bay to identify the microbial contributors of protection and to develop targeted probiotic-based therapies. In 'Bedside to Bench', Ying Taur and Eric Pamer discuss the potential of fecal microbiota transplantation (FMT) and peruse mechanisms to explain its efficacy. Alteration of bile salts, which are involved in germination of C. difficile spores, by the healthy microbiota may explain why microbiome depletion upon antibiotic treatment can lead to pathogen overgrowth. In 'Bench to Bedside', Ruth Ley peruses a recent study suggesting that sialic acids increasingly released by gut commensals after antibiotic treatment may play a crucial part in boosting C. difficile growth. Starving the pathogen of this carbohydrate in the gut by FMT or, more specifically, with engineered probiotics that can outcompete the pathogen for sialic acids may prove effective to treat or even prevent C. difficile infection.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rupnik, M., Wilcox, M.H. & Gerding, D.N. Nat. Rev. Microbiol. 7, 526–536 (2009).
Kelly, C.P. & LaMont, J.T. N. Engl. J. Med. 359, 1932–1940 (2008).
Kassam, Z., Lee, C.H., Yuan, Y. & Hunt, R.H. Am. J. Gastroenterol. 108, 1538 (2013).
Cohen, S.H. et al. Infect. Control Hosp. Epidemiol. 31, 431–455 (2010).
van Nood, E. et al. N. Engl. J. Med. 368, 407–415 (2013).
Tvede, M. & Rask-Madsen, J. Lancet 1, 1156–1160 (1989).
Shahinas, D. et al. MBio 3, e00338-12 (2012).
Emanuelsson, F., Claesson, B.E., Ljungstrom, L., Tvede, M. & Ung, K.A. Scand. J. Infect. Dis. 46, 89–97 (2013).
Lawley, T.D. et al. PLoS Pathog. 8, e1002995 (2012).
Petrof, E.O. et al. Microbiome 1, 3 (2013).
Reeves, A.E., Koenigsknecht, M.J., Bergin, I.L. & Young, V.B. Infect. Immun. 80, 3786–3794 (2012).
Smith, P.M. et al. Science 341, 569–573 (2013).
Sorg, J.A. & Sonenshein, A.L. J. Bacteriol. 190, 2505–2512 (2008).
Sorg, J.A. & Sonenshein, A.L. J. Bacteriol. 192, 4983–4990 (2010).
Giel, J.L., Sorg, J.A., Sonenshein, A.L. & Zhu, J. PLoS ONE 5, e8740 (2010).
Fimlaid, K.A. et al. PLoS Genet. 9, e1003660 (2013).
Deakin, L.J. et al. Infect. Immun. 80, 2704–2711 (2012).
Francis, M.B., Allen, C.A., Shrestha, R. & Sorg, J.A. PLoS Pathog. 9, e1003356 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Taur, Y., Pamer, E. Harnessing Microbiota to Kill a Pathogen: Fixing the microbiota to treat Clostridium difficile infections. Nat Med 20, 246–247 (2014). https://doi.org/10.1038/nm.3492
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3492